Orange Book product · Generic (ANDA)
ERIBULIN MESYLATE
ERIBULIN MESYLATE
At a glance
Oct 01, 2024
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 01, 2024
1 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
ERIBULIN MESYLATE
Strength
1MG/2ML (0.5MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
AP
Application
ANDA 217250
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ERIBULIN MESYLATE
- 2010HALAVENBrand (NDA)
NDA 201532 · EISAI INC
- 2026ERIBULIN MESYLATEGeneric (ANDA)
ANDA 217085 · NATCO
- 2026ERIBULIN MESYLATEGeneric (ANDA)
ANDA 219054 · XGEN PHARMS
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218142 · GLENMARK PHARMS
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 217473 · DR REDDYS
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 214310 · SANDOZ
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218743 · CHIA TAI TIANQING
- 2024ERIBULIN MESYLATEGeneric (ANDA)
ANDA 214850 · LONG GROVE PHARMS
- 2024ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218281 · JIANGXI KVVIT PHARM
- 2024ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218047 · GLAND
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
